CA2939655A1 - Modulators of caspase-6 - Google Patents

Modulators of caspase-6 Download PDF

Info

Publication number
CA2939655A1
CA2939655A1 CA2939655A CA2939655A CA2939655A1 CA 2939655 A1 CA2939655 A1 CA 2939655A1 CA 2939655 A CA2939655 A CA 2939655A CA 2939655 A CA2939655 A CA 2939655A CA 2939655 A1 CA2939655 A1 CA 2939655A1
Authority
CA
Canada
Prior art keywords
treatment
caspase
neurological disease
pharmaceutical composition
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2939655A
Other languages
English (en)
French (fr)
Inventor
Medhi Mike Khankischpur
Olga PETINA
Detlef Geffken
Dagmar ERNHOEFER
Michael Hayden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Universitaet Hamburg
Original Assignee
University of British Columbia
Universitaet Hamburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia, Universitaet Hamburg filed Critical University of British Columbia
Publication of CA2939655A1 publication Critical patent/CA2939655A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/28—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having nitrogen atoms of imino groups acylated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2939655A 2014-02-14 2015-02-14 Modulators of caspase-6 Abandoned CA2939655A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61/939,922 2014-02-14
US201462033401P 2014-08-05 2014-08-05
US62/033,401 2014-08-05
PCT/IB2015/000144 WO2016020732A1 (en) 2014-08-05 2015-02-14 Modulators of caspase-6

Publications (1)

Publication Number Publication Date
CA2939655A1 true CA2939655A1 (en) 2016-02-11

Family

ID=55263221

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2939655A Abandoned CA2939655A1 (en) 2014-02-14 2015-02-14 Modulators of caspase-6

Country Status (6)

Country Link
EP (1) EP3129027A4 (de)
JP (1) JP2018522812A (de)
AU (1) AU2015298491A1 (de)
CA (1) CA2939655A1 (de)
DE (1) DE112015001269T5 (de)
WO (1) WO2016020732A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017011269A (es) 2015-03-06 2018-01-12 Pharmakea Inc Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos.
JP6800872B2 (ja) 2015-03-06 2020-12-16 ファーマケア，インク． リシルオキシダーゼ様２阻害剤とその使用
EP3414229B1 (de) 2016-02-09 2021-06-16 Pharmakea, Inc. Chinolin-lysyl-oxidase-like-2-inhibitoren und verwendungen davon
JP7079772B2 (ja) 2016-09-07 2022-06-02 ファーマケア，インク． リシルオキシダーゼ様２阻害剤の結晶形態および製造方法
KR102615565B1 (ko) 2016-09-07 2023-12-18 파마케아, 인크. 리실 옥시다제 유사 2 억제제의 용도
CN115335039A (zh) * 2019-11-22 2022-11-11 加利福尼亚大学董事会 胱天蛋白酶6抑制剂和其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0818439B1 (de) * 1996-07-02 1999-10-13 Nisshin Flour Milling Co., Ltd. Imid derivate
CN101605779B (zh) * 2006-12-15 2013-11-20 百时美施贵宝公司 作为凝血因子xia抑制剂的芳基丙酰胺、芳基丙烯酰胺、芳基丙炔酰胺或芳基甲基脲类似物
US8518942B2 (en) * 2008-08-06 2013-08-27 Buck Institute For Research On Aging Caspase inhibitors and uses thereof

Also Published As

Publication number Publication date
JP2018522812A (ja) 2018-08-16
AU2015298491A1 (en) 2016-09-01
EP3129027A4 (de) 2017-06-21
WO2016020732A1 (en) 2016-02-11
DE112015001269T5 (de) 2017-06-08
EP3129027A1 (de) 2017-02-15

Similar Documents

Publication Publication Date Title
CA2939655A1 (en) Modulators of caspase-6
AU2017201599B2 (en) APP SPECIFIC BACE INHIBITORS (ASBIs) AND USES THEREOF
Kuo et al. Optimized liposomes with transactivator of transcription peptide and anti-apoptotic drugs to target hippocampal neurons and prevent tau-hyperphosphorylated neurodegeneration
EP2420235A1 (de) Verfahren und Kombinationstherapien zur Behandlung von Alzheimer
WO2009047728A2 (en) New s-acyl-glutathione derivatives, their syntesis and use in the treatment of oxidative stress-related diseases
Parsons et al. MRZ-99030–A novel modulator of Aβ aggregation: I–mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD)
US9974767B2 (en) Statins in the treatment of muscular dystrophies and myopathies
CA3154596A1 (en) Solid compositions comprising a pcsk9 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
JP6595345B2 (ja) コンフォメーション病におけるβタンパク質凝集の新規の分子モジュレーターとしての化学シャペロニン
JP2023057082A (ja) ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法
WO2010102248A2 (en) Molecular tweezers for the treatment of amyloid-related diseases
EP1931394A2 (de) Apoe4-domänen-interaktionshemmer und anwendungsverfahren dafür
CN116867488A (zh) 用于治疗干性老年性黄斑变性（amd）的组合物
US20190192524A1 (en) Modulators of Caspase-6
JP2019503356A (ja) エンドソーマルｇタンパク質共役受容体のトリパータイト・モジュレーター
CA3144618A1 (en) Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
JP6314135B2 (ja) ｉｎ−ｖｉｖｏで神経変性疾患（特にアルツハイマー病）に活性なリポソーム
EP1931656B1 (de) Neue arzneimittel gegen demenz
KR20210093900A (ko) 젬카빈, 이의 약학적으로 허용가능한 염, 이의 조성물 및 이의 사용 방법
WO2017222042A1 (ja) 眼用医薬組成物
Imbimbo et al. Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer’s disease
HUE034353T2 (en) Preparation containing a benzothiazolone compound
US20130102538A1 (en) Method of treating alzheimer's disease using pharmacological chaperones to increase presenilin function and gamma-secretase activity
WO2024004231A1 (ja) γセクレターゼ阻害剤、Ａβペプチド産生抑制剤及び医薬
US20210260153A1 (en) Use of cyclosporine analogues for treating fibrosis

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20200214